Comparison of sorafenib-loaded poly (Lactic/Glycolic) acid and dppc liposome nanoparticles in the in vitro treatment of renal cell carcinoma

Journal of Pharmaceutical Sciences

Volumn 104, Issue 3, 2015, Pages 1187-1196

  Liu, James ^a   Boonkaew, Benjawan ^b   Arora, Jaspreet ^b   Mandava, Sree Harsha ^a   Maddox, Michael M ^a   Chava, Srinivas ^a   Callaghan, Cameron ^a   He, Jibao ^b   Dash, Srikanta ^a   John, Vijay T ^b   Lee, Benjamin R ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Tulane University   (United States)

Author keywords

Cancer chemotherapy; Chitosan; Drug transport; Liposomes; Nanotechnology; Poly (lactic glycolic) acid (PLGA)

Indexed keywords

CHITOSAN; DIPALMITOYLPHOSPHATIDYLCHOLINE; POLYGLYCOLIC ACID; POLYLACTIC ACID; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG CARRIER; LACTIC ACID; LIPOSOME; NANOPARTICLE; NICOTINAMIDE; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; CANCER INHIBITION; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; KIDNEY CARCINOMA; MORPHOLOGY; PARTICLE SIZE; RENAL CELL CARCINOMA CELL LINE; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CHEMICAL PHENOMENA; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; KIDNEY NEOPLASMS; KINETICS; MEDICINAL CHEMISTRY; NANOTECHNOLOGY; PATHOLOGY; PHARMACEUTICS; PROCEDURES; SOLUBILITY; TUMOR CELL LINE;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KIDNEY NEOPLASMS; KINETICS; LACTIC ACID; LIPOSOMES; NANOPARTICLES; NANOTECHNOLOGY; NIACINAMIDE; PHENYLUREA COMPOUNDS; POLYGLYCOLIC ACID; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84922763495     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24318     Document Type: Article

References (31)

1. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. 2008. New frontiers in nanotechnology for cancer treatment. Urol Oncol 26: 74-85.
2. Kanesvaran R, Tan MH. 2014. Targeted therapy for renal cell carcinoma: The next lap. J Carcinog 13: 3.
3. Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. 2011. The epidemiology of renal cell carcinoma. Eur Urol 60: 615-621.
4. Gupta K, Miller JD, Li, JZ, Russell MW, Charbonneau C. 2008. Epidemioloic and socioeconomics burden of metastatic renal cell carcinoma (mRCC) : A literature review. Cancer Treatment Reviews 34: 193-205.
5. Wang XQ, Fan JM, Liu YO, Zhao B, Jia ZR, Zhang Q. 2011. Bioavailability and pharmacokinetics of Sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm 419: 339-346.
6. Rink JS, Plebanek MP, Tripathy S, Thaxton CS. 2013. Update on current and potential nanoparticle cancer therapies. Curr Opin Oncol 25: 646-651.
7. Cho K,Wang X, Nie S, Chen Z, Shin DM. 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14: 1310-1316.
8. Lammers T, Kiessling F, Hennink WE, Storm G. 2012. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release 161: 175-187.
9. Phan JH, Moffitt RA, Stokes TH, Liu J,Young AN, Nie S, Wang MD. 2009. Convergence of biomarkers, informatics and nanotechnology for individualized cancer treatment. Trends Biotechnol 27: 350-358.
10. Lebdai S, Verhoest G, Parikh H, et al. 2014. Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma. Urol Oncol. [Published online ahead of print July 14, 2014]
11. Gao CL, Pan J, Lu WY, Zhange M, Zhou L, Tian J. 2009. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells. Anti-Cancer Drugs 20: 807-814.
12. Kroon J, Metselaar JM, Storm G, Pluijim GVD. 2014 Liposomal nanomedicines in the treatment of prostate cancer. Cancer Treat Rev 40: 574-584.
13. Gonçalves MO, Pohlmann AR, Silveira NP, Guterres SS. 2012. Chitosan coated liposomes as an innovative nanocarrier for drugs. J Biomed Nanotechnol 8: 240-250.
14. Dowling MB, Javvaji V, Payne GF, Raghavan SR. 2010. Vesicle capture on patterned surfaces coated with amphiphilic biopolymers. Soft Matter 7: 1219-1226.
15. Bao W, Zhuo J, Luo J,Wu DX. 2006. PLGA microspheres with high drug loading and high encapsulation efficiency prepared by a novel solvent evaporation technique. J Microencapsul 23: 471-479.
16. Desbrières J, Martinezb C, Rinaudob M. 1996. Hydrophobic derivatives of chitosan: Characterization and rheological behaviour. Int J Biol Macromol 19: 21-28.
17. Wu LQ, Yi H, Li S, Rubloff GW, Bentley WE, Ghodissi R, Payne GF. 2003. Spatially selective deposition of a reactive polysaccharide layer onto a patterned template. Langmuir 19: 519-524.
18. MacGregor WS. 1967. The chemical and physical properties of DMSO Ann NY Acad Sci 141: 3-12.
19. Galvao J, Davis B, Tilley M, Normando E, Duchen MR, Cordeiro MF. 2014. Unexpected low-dose toxicity of the universal solvent DMSO. FASEB J 3: 1317-1330.
20. Muller RH, Jacobs C, Kayser O. 2001. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47: 3-19.
21. Mohammed AR, Weston N, Coombes AGA, Fitzgerald M, Perrie Y. 2004. Liposome formulation of poorly water soluble drugs: Optimisation of drug loading and ESEM analysis of stability. Int J Pharm 285: 23-34.
22. Shi Z, Guo R, Li W, Zhang Y, Xue W, Tang Y, Zhang Y. 2014. Nanoparticles of deoxycholic acid, polythylene glycol, and folic acid-modified chitosan for targeted delivery of doxorubicin. J Mater Sci 25: 723-731.
23. Yhee JY, Son S, Kim SH, Park K, Choi K, Kwon IC. 2014, May 17. Self-Assembled glycol chitosan nanoparticles for diseae-specific theranostics. J Control Release.193: 202-213.
24. Channarong S, Chaicumpa W, Sinchaipanid N, Mitrevej A. 2011. Development and evaluation of chitosan-coated liposomes for oral DNA vaccine. AAPS PharmSciTech 12: 182-200.
25. Liu R, Gan L, Yang X, Xu H. 2011. Chitosan as a condensing agent induced high gene transfection efficiency and low cytotoxicity of liposome. J Biosci Bioeng 111: 98-103.
26. Mady MM, Darwish MM. 2010. Effect of chitosan coating on the characteristics of DPPC liposomes. J Adv Res 1: 187-191.
27. John V, Zheng R. 2014. Biopolymer hooks to create coatings on liposomes. US20140017298 A1.
28. Attwood SJ, Choi Y, Leonenko Z. 2013. Preparation of DOPC and DPPC supported planar lipid bilayers for atomic force microscopy and atomic force spectroscopy. Int J Mol Sci 14: 3514-3539.
29. Hans ML, Lowman AM. 2002. Biodegradable nanoparticle drug delivery and targeting. Curr Opin Solid State Mater Sci 6: 319-327.
30. Mukherjee SG, O'Claonadh N, Casey A, Chambers G. 2012. Comparative in vitro cytotoxicity study of silver nanoparticle on two mammalian cell lines. Toxicol In Vitro 26: 238-251.
31. Boonkaew B, Kempf M, Kimble R, Cuttle L. Cytotoxicity testing of silver-containing burn treatments using primary and immortal skin cells. Burns 40: 1562-1569.